

Cover Story
This was not your ordinary ODAC, but a three-day checkpoint inhibitor marathon that consumed April 27, 28, and 29. You might call it six ODACs for the price of one: subtle as all get-out, if-you-blink-you-miss-it head-spinner of a shindig.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Why both somatic and germline genomic profiling are essential for precision oncology

















